FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 339:2022-2023 December 31, 1998 Number 27 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Gottlieb, S. S. PubMed Citation

To the Editor: In their report on an observational study of beta-blockade after myocardial infarction, Gottlieb et al. (Aug. 20 issue)¹ firmly conclude that beta-blockers should be used for high-risk patients after acute myocardial infarction, including patients with congestive heart failure. This conclusion is not supported by the data presented. The randomized studies of beta-blockers excluded patients with severe heart failure — and all physicians are trained in such contraindications. Therefore, we know that physicians will be reluctant to use beta-blockers in high-risk patients, and we can readily anticipate that the willingness to use a beta-blocker is a marker of . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.